Midlife weight gain has metabolic + behavioral + hormonal drivers. GLP-1 medications are increasingly first-line for clinically significant cases.
Women gain average 1.5 lbs/year during midlife (CARDIA, SWAN). Estrogen decline shifts fat distribution к visceral; muscle mass declines с aging. Treatment depends на BMI + comorbidities.
Universal к some degree в midlife. Becomes clinically significant when BMI ≥30 OR ≥27 с weight-related condition (hypertension, dyslipidemia, type 2 diabetes, sleep apnea).
All options below are real published treatments. Evidence-level reflects current clinical guidelines (NAMS / ACOG / Endocrine Society). Cost ranges are starting price estimates от $US public sources.
Monthly cost
$25 (insurance) - $1349 (cash)
Side effects
nausea, constipation, GI upset, rare gastroparesis
Wegovy ~15% body weight loss, Zepbound ~22% over 68 weeks. Best efficacy of available pharmacotherapy.
Contraindications: Personal/family history of medullary thyroid cancer, MEN2
Providers offering this: joi womens wellness, noom med, calibrate insurance
Monthly cost
$150-$500
Side effects
same as brand
Same active molecule as brand-name. Lower cost но requires а 503A/503B compounder с valid medical-necessity rationale. Quality / sterility varies by pharmacy.
Providers offering this: hers weight loss, plushcare glp1
Monthly cost
$0-$50
Side effects
minimal
Critical regardless of pharmacotherapy. Preserves muscle (which preserves metabolic rate). 1.2-1.6 g/kg protein daily.
Monthly cost
$20-$200
Side effects
varies by drug
Modest 5-8% weight loss. Useful когда GLP-1 contraindicated, unavailable, OR too expensive.
Yes typically — ~⅔ of lost weight returns within 1 year of discontinuation per STEP-4 trial. GLP-1s for weight management are typically long-term meds, similar к BP / cholesterol meds.
Last verified 2026-06-01. Treatment guidelines update — confirm с your clinician.